Vistagen Therapeutics Analyst Ratings
Vistagen Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/05/2023 | 388.61% | Maxim Group | $30 → $30 | Maintains | Buy |
| 08/07/2023 | 388.61% | Maxim Group | → $30 | Upgrades | Hold → Buy |
| 07/26/2022 | — | Maxim Group | Downgrades | Buy → Hold | |
| 07/22/2022 | — | William Blair | Downgrades | Outperform → Market Perform | |
| 05/20/2021 | 46.58% | Baird | → $9 | Initiates Coverage On | → Outperform |
| 02/18/2021 | -2.28% | Jefferies | → $6 | Initiates Coverage On | → Buy |
| 01/04/2021 | — | William Blair | Upgrades | Market Perform → Outperform | |
| 10/08/2020 | -2.28% | Aegis Capital | → $6 | Initiates Coverage On | → Buy |
| 08/28/2019 | — | William Blair | Initiates Coverage On | → Outperform | |
| 07/22/2019 | -88.6% | Chardan Capital | $22 → $0.7 | Downgrades | Buy → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 09/05/2023 | 388.61% | Maxim 集團 | 30 美元 → 30 美元 | 維護 | 購買 |
| 08/07/2023 | 388.61% | Maxim 集團 | → 30 美元 | 升級 | 持有 → 買入 |
| 07/26/2022 | — | Maxim 集團 | 降級 | 買入 → 持有 | |
| 07/22/2022 | — | 威廉布萊爾 | 降級 | 跑贏大盤 → 市場表現 | |
| 2021 年 5 月 20 日 | 46.58% | 貝爾德 | → 9 美元 | 啓動覆蓋開啓 | → 跑贏大盤 |
| 2021 年 2 月 18 日 | -2.28% | 傑富瑞 | → 6 美元 | 啓動覆蓋開啓 | → 購買 |
| 01/04/2021 | — | 威廉布萊爾 | 升級 | 市場表現 → 跑贏大盤 | |
| 2020 年 8 月 10 日 | -2.28% | 宙斯盾資本 | → 6 美元 | 啓動覆蓋開啓 | → 購買 |
| 08/28/2019 | — | 威廉布萊爾 | 啓動覆蓋開啓 | → 跑贏大盤 | |
| 07/22/2019 | -88.6% | 查丹資本 | 22 美元 → 0.7 美元 | 降級 | 買入 → 中性 |
What is the target price for Vistagen Therapeutics (VTGN)?
Vistagen Therapeutics（VTGN）的目標價格是多少？
The latest price target for Vistagen Therapeutics (NASDAQ: VTGN) was reported by Maxim Group on September 5, 2023. The analyst firm set a price target for $30.00 expecting VTGN to rise to within 12 months (a possible 388.61% upside). 2 analyst firms have reported ratings in the last year.
Maxim集團於2023年9月5日公佈了Vistagen Therapeutics（納斯達克股票代碼：VTGN）的最新目標股價。該分析公司將目標股價定爲30.00美元，預計VTGN將在12個月內上漲至38.61％（可能上漲388.61％）。去年，有2家分析公司公佈了評級。
What is the most recent analyst rating for Vistagen Therapeutics (VTGN)?
分析師對Vistagen Therapeutics（VTGN）的最新評級是多少？
The latest analyst rating for Vistagen Therapeutics (NASDAQ: VTGN) was provided by Maxim Group, and Vistagen Therapeutics maintained their buy rating.
Vistagen Therapeutics（納斯達克股票代碼：VTGN）的最新分析師評級由Maxim集團提供，Vistagen Therapeutics維持買入評級。
When is the next analyst rating going to be posted or updated for Vistagen Therapeutics (VTGN)?
Vistagen Therapeutics（VTGN）的下一個分析師評級何時公佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Vistagen Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Vistagen Therapeutics was filed on September 5, 2023 so you should expect the next rating to be made available sometime around September 5, 2024.
分析師在進行了廣泛的研究後得出了股票評級，包括閱讀公開財務報表、與Vistagen Therapeutics的高管和客戶交談以及聽取業績電話會議。大多數分析師每三個月進行一次評級，因此每家公司每年應獲得4個評級。Vistagen Therapeutics的最新評級是在2023年9月5日提交的，因此你應該預計下一個評級將在2024年9月5日左右公佈。
Is the Analyst Rating Vistagen Therapeutics (VTGN) correct?
分析師對Vistagen Therapeutics（VTGN）的評級正確嗎？
While ratings are subjective and will change, the latest Vistagen Therapeutics (VTGN) rating was a maintained with a price target of $30.00 to $30.00. The current price Vistagen Therapeutics (VTGN) is trading at is $6.14, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Vistagen Therapeutics（VTGN）評級保持不變，目標股價爲30.00美元至30.00美元。Vistagen Therapeutics（VTGN）目前的交易價格爲6.14美元，超出了分析師的預期區間。
譯文內容由第三人軟體翻譯。